LungLife AI, INC Block Listing Six Monthly Return (4978L)

TIDMLLAI

RNS Number : 4978L

LungLife AI, INC

16 May 2022

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 
 Name of applicant:                        LungLife AI, Inc. 
 Name of scheme:                                1. 2010 Stock Incentive Plan 
                                                 2. 2020 Stock Incentive Plan 
                                                 3. 2021 Omnibus Long-Term Incentive 
                                                 Plan 
                                          ---------------------------------------------- 
 Number and class of securities            1,356,139 common shares of US 
  originally admitted:                      $0.0001 each 
                                          ---------------------------------------------- 
 Date of admission:                        15 November 2021 
                                          ---------------------------------------------- 
 Period of return:               From:     15 November        To:    15 May 2022 
                                            2021 
                                --------  -----------------  -----  -------------------- 
 Balance of unallotted securities               1. 480,775 
  under scheme(s) from previous 
  return: 
                                                 2. 201,374 
                                                 3. 673,990 
                                          ---------------------------------------------- 
 Plus: The amount by which the                  1. NIL 
  block scheme(s) has been increased             2. NIL 
  since the date of the last                     3. NIL 
  return (if any increase has 
  been applied for): 
                                          ---------------------------------------------- 
 Less: Number of securities                     1. NIL 
  issued/allotted under scheme(s)                2. NIL 
  during period (see LR3.5.7G):                  3. NIL 
                                          ---------------------------------------------- 
 Equals: Balance under scheme(s)                1. 480,775 
  not yet issued/allotted at 
  end of period: 
                                                 2. 201,374 
                                                 3. 673,990 
                                          ---------------------------------------------- 
 Total number of securities 
  in issue at the end of the 
  period                                   25,480,790 
                                          ---------------------------------------------- 
 
 
 
 Name of contact:               David Anderson, Chief Financial 
                                 Officer 
 Telephone number of contact:   + 44 (0)20 7933 8780 or lunglifeai@walbrookpr.com 
                               --------------------------------------------------

For further information please contact:

 
LungLife AI, Inc.                                 www.lunglifeai.com 
Paul Pagano, CEO                                     Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser        Tel: +44 (0)20 7597 5970 
 & Broker) 
Daniel Adams / Virginia Bull / Cameron 
 MacRitchie 
 
Walbrook PR Limited                      Tel: +44 (0)20 7933 8780 or 
                                           LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings             Mob: 07980 541 893 / 07407 
                                                             804 654

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRGPUCGAUPPGCW

(END) Dow Jones Newswires

May 16, 2022 02:01 ET (06:01 GMT)

Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024